Aktienanalyse zu Inovio Pharmaceuticals Inc (INO)INOInovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Inovio Pharmaceuticals Inc is currently not a strong buy due to its recent performance and financial metrics. The stock is priced at $0.9901, down 41.41% year-to-date and 59.91% over the past year. The RSI is at 32.396, indicating it is approaching oversold territory, but the forward P/E ratio of 16.5837 suggests potential future earnings growth. The main risk is the recent public offering that caused a 20% drop in after-hours trading, reflecting market concerns about dilution.

6 analysts cover INO: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 7.33.